Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

HealthTree Podcast for MM

HealthTree Podcast for Multiple Myeloma


Follow This Show

Stay in the know about new episodes and updates.
HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

Upcoming Broadcasts

Bispecific antibodies are an increasingly popular choice for relapsed/refractory myeloma care. Learn more about this type of treatment with Dr. Alfred Garfall and Dr. Bea Razzo in this HealthTree Podcast. They will cover the FDA approved bispecific antibodies, those in development, how this changes the myeloma treatment landscape, sequencing, side effects and new strategies like a fixed duration that may reduce the treatment burden for patients. Thanks to our episode sponsor, Genentech
  • by HealthTree Podcast for MM
  • in Health
  • 01:30

On-Demand Episodes

CAR T therapy is a highly effective treatment for myeloma patients, even in highly relapsed multiple myeloma. In today's show we will hear from Luciano Costa, MD of the University of Burmingham who will do a deep dive into CAR T therapy... more

Dr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. Updates will... more

Stem cell transplant remains a useful and widely used treatment for multiple myeloma. John DiPersio, MD, PhD of the Siteman Cancer Center at Washington University joins HealthTree Podcast for Multiple Myeloma to discuss stem cell... more

The cure for multiple myeloma only happens with patient participation in research. In this episode, Faith Davies, MBBCh, MRCP, MD, FRCPath of the NYU Langone will share how research works in multiple myeloma, the various stages in... more

Minimal Residual Disease (MRD) testing is a more sensitive way to test for remaining disease following myeloma treatment. Its use could change the way experts treat multiple myeloma now and in the future. MRD testing may help... more

A wave of blood-based tests are being researched for myeloma care, and for good reason. Patients love the idea of replacing the painful bone marrow biopsy with a blood-based test, especially if it is equally effective. In addition to being... more

Dr. Noa Biran of Hackensack University joins HealthTree Podcast for Multiple Myeloma to discuss a completely new approach targeting CD38, which is found on most myeloma cells. The drug called modafakusp alpha (formerly known... more

There are significant advances being made in multiple myeloma and more so than in any other cancer. Join us for this annual show with Robert Orlowski, MD, PhD as we discuss the recent findings from the American Society of... more

Teclistamab is the first bispecific antibody to be FDA approved in mulitple myeloma. On this HealthTree Podcast for Multiple Myeloma episode, learn from Alfred Garfall, MD of the University of Pennsylvania about how it will be used in... more

Over 40% of multiple myeloma patients deal with kidney disease during their multiple myeloma journey. Learn more from Natalie Callander, MD of the University of Wisconsin at Madison about how myeloma affects the kidneys,... more
Show Extras

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled